Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program

BACKGROUND: Disease modifying treatments (DMT) for MS such as interferon beta (IFNβ) have been shown to reduce the risk for disease progression. Therefore adherence to treatment is essential for treatment outcome.Here we want to evaluate if participation in a patient management program (PMP) improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsarava, Zaza, Ehlken, Birgit, Limmroth, Volker, Taipale, Kirsi, Patel, Sarita Noemi, Niemczyk, Gabriele, Rehberg-Weber, Karin, Wernsdörfer, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580346/
https://www.ncbi.nlm.nih.gov/pubmed/26395989
http://dx.doi.org/10.1186/s12883-015-0426-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580346/
https://www.ncbi.nlm.nih.gov/pubmed/26395989
http://dx.doi.org/10.1186/s12883-015-0426-x

Ejemplares similares